Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP773979.RAnu4lVHwDKW_nvcooVkOU4rlhyK5I4u9e1f8JygeYUb8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP773979.RAnu4lVHwDKW_nvcooVkOU4rlhyK5I4u9e1f8JygeYUb8130_assertion type Assertion NP773979.RAnu4lVHwDKW_nvcooVkOU4rlhyK5I4u9e1f8JygeYUb8130_head.
- NP773979.RAnu4lVHwDKW_nvcooVkOU4rlhyK5I4u9e1f8JygeYUb8130_assertion description "[Good examples are (1) trastuzumab, hMAB against HER2 in breast cancers with HER2 over-expression and amplification, (2) imatinib, TKI, for gastrointestinal stromal tumors (GISTs) with c-kit mutation, (3) gefitinib, TKI, for lung adenocarcinoma with EGFR mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP773979.RAnu4lVHwDKW_nvcooVkOU4rlhyK5I4u9e1f8JygeYUb8130_provenance.
- NP773979.RAnu4lVHwDKW_nvcooVkOU4rlhyK5I4u9e1f8JygeYUb8130_assertion evidence source_evidence_literature NP773979.RAnu4lVHwDKW_nvcooVkOU4rlhyK5I4u9e1f8JygeYUb8130_provenance.
- NP773979.RAnu4lVHwDKW_nvcooVkOU4rlhyK5I4u9e1f8JygeYUb8130_assertion SIO_000772 19891708 NP773979.RAnu4lVHwDKW_nvcooVkOU4rlhyK5I4u9e1f8JygeYUb8130_provenance.
- NP773979.RAnu4lVHwDKW_nvcooVkOU4rlhyK5I4u9e1f8JygeYUb8130_assertion wasDerivedFrom befree-2016 NP773979.RAnu4lVHwDKW_nvcooVkOU4rlhyK5I4u9e1f8JygeYUb8130_provenance.
- NP773979.RAnu4lVHwDKW_nvcooVkOU4rlhyK5I4u9e1f8JygeYUb8130_assertion wasGeneratedBy ECO_0000203 NP773979.RAnu4lVHwDKW_nvcooVkOU4rlhyK5I4u9e1f8JygeYUb8130_provenance.